• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, July 23, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Chemistry

Reduced-dose gadobutrol vs standard-dose gadoterate for contrast-enhanced brain MRI

Bioengineer by Bioengineer
June 17, 2021
in Chemistry
Reading Time: 2 mins read
0
ADVERTISEMENT
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A 25% reduced gadobutrol dose demonstrated non-inferior efficacy versus 100%-standard dose of gadoterate for contrast-enhanced brain MRI, particularly in patients undergoing multiple contrast-enhanced examinations

IMAGE

Credit: American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

Leesburg, VA, June 17, 2021–According to ARRS’ American Journal of Roentgenology (AJR), a reduced dose of gadobutrol is non-inferior to 100%-standard dose of gadoterate for contrast-enhanced brain MRI.

“A 25% reduced gadobutrol dose demonstrated non-inferior efficacy versus standard dose gadoterate for contrast-enhanced brain MRI,” corresponding author Jan Endrikat of Germany’s University Medical School of Saarland elaborated, “warranting particular consideration in patients undergoing multiple contrast-enhanced examinations.”

In this international, prospective, multicenter, open-label, crossover trial (LEADER-75), 141 patients (78 men, 63 women; mean age, 58.5 years) with known or suspected CNS pathology underwent contrast-enhanced brain MRI with standard-dose gadoterate (0.1 mmol/ kg). If an enhancing lesion was identified, a second MRI with reduced-dose gadobutrol (0.075 mmol/kg) was performed within 15 days.

Comparison of reduced-dose gadobutrol and standard-dose gadoterate versus unenhanced imaging demonstrated noninferiority using 20% margin for three primary efficacy measures: subjective lesion enhancement, lesion border delineation, lesion internal morphology.

Furthermore, in post-hoc analysis, mean readings for subjective lesion enhancement, lesion border delineation, and lesion internal morphology differed by less than 1%–supporting equivalence using a narrow ±5% margin.

“Various secondary variables also supported non-inferiority of reduced-dose gadobutrol,” the authors of the AJR article added.

###

Founded in 1900, the American Roentgen Ray Society (ARRS) is the first and oldest radiological society in North America, dedicated to the advancement of medicine through the profession of radiology and its allied sciences. An international forum for progress in medical imaging since the discovery of the x-ray, ARRS maintains its mission of improving health through a community committed to advancing knowledge and skills with an annual scientific meeting, monthly publication of the peer-reviewed American Journal of Roentgenology (AJR), quarterly issues of InPractice magazine, AJR Live Webinars and Podcasts, topical symposia, print and online educational materials, as well as awarding scholarships via The Roentgen Fund®.

Media Contact
Logan K. Young
[email protected]

Original Source

https://arrs.org/ARRSLIVE/Pressroom/PressReleases/Reduced_Gadobutrol_vs_Standard_Gadoterate_Contrast-Enhanced_Brain_MRI.aspx

Related Journal Article

http://dx.doi.org/10.2214/AJR.21.25924

Tags: Clinical TrialsDiagnosticsHealth Care Systems/ServicesMedicine/HealthneurobiologyNeurochemistryPharmaceutical ChemistryPharmaceutical Science
Share13Tweet8Share2ShareShareShare2

Related Posts

Architecture of VBayesMM

Unraveling Gut Bacteria Mysteries Through AI

July 4, 2025
Visulaization of ATLAS collision

Can the Large Hadron Collider Prove String Theory Right?

July 3, 2025

Breakthrough in Gene Therapy: Synthetic DNA Nanoparticles Pave the Way

July 3, 2025

Real-Time Electrochemical Microfluidic Monitoring of Additive Levels in Acidic Copper Plating Solutions for Metal Interconnections

July 3, 2025
Please login to join discussion

POPULAR NEWS

  • Blind to the Burn

    Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    58 shares
    Share 23 Tweet 15
  • New Organic Photoredox Catalysis System Boosts Efficiency, Drawing Inspiration from Photosynthesis

    54 shares
    Share 22 Tweet 14
  • IIT Researchers Unveil Flying Humanoid Robot: A Breakthrough in Robotics

    53 shares
    Share 21 Tweet 13
  • AI Achieves Breakthrough in Drug Discovery by Tackling the True Complexity of Aging

    70 shares
    Share 28 Tweet 18

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Additive Manufacturing of Monolithic Gyroidal Solid Oxide Cells

Machine Learning Uncovers Sorghum’s Complex Mold Resistance

Pathology Multiplexing Revolutionizes Disease Mapping

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.